According to a recent LinkedIn post from Truveta, the company’s research arm has released a new GLP-1 monitoring report covering data through March 2026. The post highlights that in March 2026, nearly 8% of all prescriptions were for GLP-1 drugs, representing the largest quarter-over-quarter increase since 2019.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The post also indicates that first-time anti-obesity medication prescribing rose 21.7% from December 2025 to March 2026, with first-time semaglutide use rising by more than 50%. The increase is described as likely influenced by the approval of the Wegovy pill, suggesting accelerating demand signals that could enhance the strategic relevance of Truveta’s real-world evidence and analytics offerings for pharmaceutical and healthcare stakeholders.
As shared in the LinkedIn update, the report appears to underscore rapid growth in a key therapeutic category that is drawing substantial investment and competitive activity. For investors, this may point to expanding opportunities for Truveta to monetize data insights, deepen collaboration with drug manufacturers and providers, and strengthen its positioning as GLP-1 utilization trends become increasingly important to payers and life sciences decision-makers.